{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:36:55Z","timestamp":1793623015739,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Preclinical studies of tifcemalimab (anti-BTLA antibody) in combination with toripalimab (anti-PD-1 antibody) demonstrated synergistic anti-tumor effects. We present the outcomes of tifcemalimab with or without toripalimab in lymphoma patients. This is a 2-part, phase I study (NCT04477772). In Part A (dose escalation based on 3\u2009+\u20093 design), patients with relapsed or refractory lymphoma received tifcemalimab monotherapy 1, 3 or 10\u2009mg\/kg for dose escalation and 3\u2009mg\/kg or 200\u2009mg for dose expansion. For Part B (indication expansion), only classical Hodgkin\u2019s lymphoma (cHL) patients were included to receive tifcemalimab 100 or 200\u2009mg plus toripalimab 240\u2009mg due to poor tumor response in other subtypes. The primary endpoints were safety, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). 25 patients in Part A and 46 in Part B were enrolled. No dose-limiting toxicities were observed, and MTD was not reached. The RP2D for tifcemalimab was 200\u2009mg. Adverse events were predominantly Grade 1\/2. Grade 3\/4 treatment-related adverse events occurred in 3 patients (12\u00b70%) in Part A and 15 patients (32\u00b76%) in Part B. No fatal adverse events were observed. Tifcemalimab with or without toripalimab demonstrated a favorable safety profile in lymphoma patients.<\/jats:p>","DOI":"10.1038\/s41467-025-59461-3","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T11:20:20Z","timestamp":1747394420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed\/refractory lymphoma: a\u00a0Phase I trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Yuqin","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuerong","family":"Shuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-2547","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"59461_CR1","doi-asserted-by":"publisher","first-page":"1067289","DOI":"10.3389\/fonc.2023.1067289","volume":"13","author":"F Ullah","year":"2023","unstructured":"Ullah, F., Dima, D., Omar, N., Ogbue, O. & Ahmed, S. Advances in the treatment of Hodgkin lymphoma: Current and future approaches. Front. Oncol. 13, 1067289 (2023).","journal-title":"Front. Oncol."},{"key":"59461_CR2","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/ajh.26717","volume":"97","author":"SM Ansell","year":"2022","unstructured":"Ansell, S. M. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 97, 1478\u20131488 (2022).","journal-title":"Am. J. Hematol."},{"key":"59461_CR3","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/ni944","volume":"4","author":"N Watanabe","year":"2003","unstructured":"Watanabe, N. et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4, 670\u2013679 (2003).","journal-title":"Nat. Immunol."},{"key":"59461_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ni1144","volume":"6","author":"JR Sedy","year":"2005","unstructured":"Sedy, J. R. et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 6, 90\u201398 (2005).","journal-title":"Nat. Immunol."},{"key":"59461_CR5","first-page":"1361","volume":"35","author":"T Inoue","year":"2015","unstructured":"Inoue, T. et al. HVEM expression contributes to tumor progression and prognosis in human colorectal cancer. Anticancer Res. 35, 1361\u20131367 (2015).","journal-title":"Anticancer Res."},{"key":"59461_CR6","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1038\/sj.leu.2403175","volume":"17","author":"RT Costello","year":"2003","unstructured":"Costello, R. T. et al. Stimulation of non-Hodgkin\u2019s lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. Leukemia 17, 2500\u20132507 (2003).","journal-title":"Leukemia"},{"key":"59461_CR7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.coph.2012.03.001","volume":"12","author":"C Pasero","year":"2012","unstructured":"Pasero, C., Speiser, D. E., Derr\u00e9, L. & Olive, D. The HVEM network: new directions in targeting novel costimulatory\/co-inhibitory molecules for cancer therapy. Curr. Opin. Pharmacol. 12, 478\u2013485 (2012).","journal-title":"Curr. Opin. Pharmacol."},{"key":"59461_CR8","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201905085","volume":"219","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. J. Cell Biol. 219, e201905085 (2020).","journal-title":"J. Cell Biol."},{"key":"59461_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","volume":"72","author":"J Fourcade","year":"2012","unstructured":"Fourcade, J. et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72, 887\u2013896 (2012).","journal-title":"Cancer Res."},{"key":"59461_CR10","doi-asserted-by":"crossref","unstructured":"Kuruvilla, J. et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study [published correction appears in Lancet Oncol. Lancet Oncol. 22, 512\u2013524 (2021)..","DOI":"10.1016\/S1470-2045(21)00005-X"},{"key":"59461_CR11","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes, A. et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 17, 1283\u20131294 (2016).","journal-title":"Lancet Oncol."},{"key":"59461_CR12","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ijc.33852","volume":"150","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study. Int. J. Cancer 150, 984\u2013992 (2022).","journal-title":"Int. J. Cancer"},{"key":"59461_CR13","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","volume":"6","author":"Y Shi","year":"2019","unstructured":"Shi, Y. et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 6, e12\u2013e19 (2019).","journal-title":"Lancet Haematol."},{"key":"59461_CR14","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1634\/theoncologist.2020-0167","volume":"25","author":"NA Carreau","year":"2020","unstructured":"Carreau, N. A. et al. Checkpoint blockade treatment may sensitize Hodgkin Lymphoma to subsequent therapy. Oncologist 25, 878\u2013885 (2020).","journal-title":"Oncologist"},{"key":"59461_CR15","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/blood-2022-166670","volume":"140","author":"J Timmerman","year":"2022","unstructured":"Timmerman, J. et al. Updated results from an oopen-label phase 1\/2 study of favezelimab (anti-LAG-3) plus pembrolizumab in relapsed or refractory classical Hodgkin Lymphoma after Anti-PD-1 treatment. Blood 140, 768\u2013770 (2022).","journal-title":"Blood"},{"key":"59461_CR16","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1182\/blood-2023-180926","volume":"142","author":"MG Mei","year":"2023","unstructured":"Mei, M. G. et al. Safety and preliminary efficacy of sabestomig (AZD7789), an anti-PD-1 and anti-TIM-3 bispecific antibody, in patients with relapsed or refractory classical Hodgkin Lymphoma previously treated with anti-PD-(L)1 therapy. Blood 142, 4433\u20134433 (2023).","journal-title":"Blood"},{"key":"59461_CR17","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1182\/blood-2023-190753","volume":"142","author":"MG Mei","year":"2023","unstructured":"Mei, M. G. et al. The combination of nivolumab and CC-486 is active in Hodgkin Lymphoma refractory to PD-1 blockade. Blood 142, 1697\u20131697 (2023).","journal-title":"Blood"},{"key":"59461_CR18","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1158\/1078-0432.CCR-21-0133","volume":"27","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin Lymphoma who progressed or relapsed after PD-1blockade monotherapy. Clin. Cancer Res. 27, 2782\u20132791 (2021).","journal-title":"Clin. Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59461-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59461-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59461-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T11:20:22Z","timestamp":1747394422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59461-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59461"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59461-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yifan Wang, Weiwei Wang, Jing Xu, Rong Deng, Qin Meng are employees of Shanghai Junshi Biosciences Co., Ltd. Other authors declare no potential competing interests for the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4559"}}